|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Poellinger A: Near-infrared imaging of
breast cancer using optical contrast agents. J Biophotonics.
5:815–826. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Onitilo AA, Engel JM, Greenlee RT and
Mukesh BN: Breast cancer subtypes based on ER/PR and Her2
expression: Comparison of clinicopathologic features and survival.
Clin Med Res. 7:4–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lohrisch C and Piccart M: HER2/neu
as a predictive factor in breast cancer. Clin Breast Cancer.
2:129–135; discussion 136–137. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fabian MR, Sundermeier TR and Sonenberg N:
Understanding how miRNAs post-transcriptionally regulate gene
expression. Prog Mol Subcell Biol. 50:1–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR,
Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant
KC, Allen A, et al: Circulating microRNAs as stable blood-based
markers for cancer detection. Proc Natl Acad Sci USA.
105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Radia AM, Yaser AM, Ma X, Zhang J, Yang C,
Dong Q, Rong P, Ye B, Liu S and Wang W: Specific siRNA targeting
receptor for advanced glycation end products (RAGE) decreases
proliferation in human breast cancer cell lines. Int J Mol Sci.
14:7959–7978. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stoetzer OJ, Fersching DM, Salat C,
Steinkohl O, Gabka CJ, Hamann U, Braun M, Feller AM, Heinemann V,
Siegele B, et al: Circulating immunogenic cell death biomarkers
HMGB1 and RAGE in breast cancer patients during neoadjuvant
chemotherapy. Tumour Biol. 34:81–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khan S, Wall D, Curran C, Newell J, Kerin
MJ and Dwyer RM: MicroRNA-10a is reduced in breast cancer and
regulated in part through retinoic acid. BMC Cancer. 15:3452015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang CH, Fan TC, Yu JC, Liao GS, Lin YC,
Shih AC, Li WH and Yu AL: The prognostic significance of RUNX2 and
miR-10a/10b and their inter-relationship in breast cancer. J Transl
Med. 12:2572014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan YZ, Morris ME and Yu AM: MicroRNA-328
negatively regulates the expression of breast cancer resistance
protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol.
75:1374–1379. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshitomi T, Kawakami K, Enokida H,
Chiyomaru T, Kagara I, Tatarano S, Yoshino H, Arimura H, Nishiyama
K, Seki N, et al: Restoration of miR-517a expression induces cell
apoptosis in bladder cancer cell lines. Oncol Rep. 25:1661–1668.
2011.PubMed/NCBI
|
|
13
|
Liu RF, Xu X, Huang J, Fei QL, Chen F, Li
YD and Han ZG: Down-regulation of miR-517a and miR-517c promotes
proliferation of hepatocellular carcinoma cells via targeting Pyk2.
Cancer Lett. 329:164–173. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou CX, Wang CL, Yu AL, Wang QY, Zhan MN,
Tang J, Gong XF, Yin QQ, He M, He JR, et al: MiR-630 suppresses
breast cancer progression by targeting metadherin. Oncotarget.
7:1288–1299. 2016.PubMed/NCBI
|
|
15
|
Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, Yao
H, Song E, Chen Y, Wang M, et al: The overexpression of
hypomethylated miR-663 induces chemotherapy resistance in human
breast cancer cells by targeting heparin sulfate proteoglycan 2
(HSPG2). J Biol Chem. 288:10973–10985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Luo EC, Chang YC, Sher YP, Huang WY,
Chuang LL, Chiu YC, Tsai MH, Chuang EY and Lai LC: MicroRNA-769-3p
down-regulates NDRG1 and enhances apoptosis in MCF-7 cells
during reoxygenation. Sci Rep. 4:59082014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiu HJ, Lu XH, Yang SS, Weng CY, Zhang EK
and Chen FC: MiR-769 promoted cell proliferation in human melanoma
by suppressing GSK3B expression. Biomed Pharmacother. 82:1172016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pu Q, Huang Y, Lu Y, Peng Y, Zhang J, Feng
G, Wang C, Liu L and Dai Y: Tissue-specific and plasma microRNA
profiles could be promising biomarkers of histological
classification and TNM stage in non-small cell lung cancer. Thorac
Cancer. 7:348–354. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fuentes MK, Nigavekar SS, Arumugam T,
Logsdon CD, Schmidt AM, Park JC and Huang EH: RAGE activation by
S100P in colon cancer stimulates growth, migration, and cell
signaling pathways. Dis Colon Rectum. 50:1230–1240. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takada M, Koizumi T, Toyama H, Suzuki Y
and Kuroda Y: Differential expression of RAGE in human pancreatic
carcinoma cells. Hepatogastroenterology. 48:1577–1578.
2001.PubMed/NCBI
|
|
21
|
Wagner NB, Weide B, Reith M, Tarnanidis K,
Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J,
Ikenberg K, et al: Diminished levels of the soluble form of RAGE
are related to poor survival in malignant melanoma. Int J Cancer.
137:2607–2617. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lerma E, Peiro G, Ramón T, Fernandez S,
Martinez D, Pons C, Muñoz F, Sabate JM, Alonso C, Ojeda B, et al:
Immunohistochemical heterogeneity of breast carcinomas negative for
estrogen receptors, progesterone receptors and Her2/neu (basal-like
breast carcinomas). Mod Pathol. 20:1200–1207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Subhawong AP, Subhawong T, Nassar H,
Kouprina N, Begum S, Vang R, Westra WH and Argani P: Most
basal-like breast carcinomas demonstrate the same Rb-/p16+
immunophenotype as the HPV-related poorly differentiated squamous
cell carcinomas which they resemble morphologically. Am J Surg
Pathol. 33:163–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Reis-Filho JS and Tutt ANJ: Triple
negative tumours: A critical review. Histopathology. 52:108–118.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, et al: Immunohistochemical and clinical characterization of the
basal-like subtype of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
El-Rehim Abd DM, Pinder SE, Paish CE, Bell
J, Blamey RW, Robertson JF, Nicholson RI and Ellis IO: Expression
of luminal and basal cytokeratins in human breast carcinoma. J
Pathol. 203:661–671. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten
DS, Nobel AB, van't Veer LJ and Perou CM: Concordance among
gene-expression-based predictors for breast cancer. N Engl J Med.
355:560–569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Han N, Zhao W, Zhang Z and Zheng P:
MiR-328 suppresses the survival of esophageal cancer cells by
targeting PLCE1. Biochem Biophys Res Commun. 470:175–180. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X and Xia Y: microRNA-328 inhibits
cervical cancer cell proliferation and tumorigenesis by targeting
TCF7L2. Biochem Biophys Res Commun. 475:169–175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen
X, Xiao SD and Ran ZH: MicroRNA expression profiling identifies
miR-328 regulates cancer stem cell-like SP cells in colorectal
cancer. Br J Cancer. 106:1320–1330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jones RL, Rojo F, A'Hern R, Villena N,
Salter J, Corominas JM, Servitja S, Smith IE, Rovira A, Reis-Filho
JS, et al: Nuclear NF-κB/p65 expression and response to neoadjuvant
chemotherapy in breast cancer. J Clin Pathol. 64:130–135. 2011.
View Article : Google Scholar : PubMed/NCBI
|
